Nycomed Strengthens Dermatology Franchise With Bradley Purchase
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss firm offers $20 per share for New Jersey specialty pharma in deal valued at around $346 million.
You may also be interested in...
Bayer Builds On Oncology Pipeline With Nycomed’s Divested Kinase Inhibitors
Acquisition of two candidates and back-up compounds complements ongoing Nexavar efforts, Bayer says.
Bayer Builds On Oncology Pipeline With Nycomed’s Divested Kinase Inhibitors
Acquisition of two candidates and back-up compounds complements ongoing Nexavar efforts, Bayer says.
Bradley Pharmaceuticals Announces Receipt Of Acquisition Bids; Ranbaxy Rumored As Possible Suitor
Announcement marks the latest episode in a saga that involves activist investors and a defensive move to take the company private.